Our aim is to develop mechanism-based specific therapy for sporadic amyotrophic
lateral sclerosis (ALS), in which RNA editing activity is not efficient
in the motor neurons.
News＆Topics
November, 2018
Presentation on the title of ”Target therapy for ALS with RNA aptamers ?rescue of ALS phenotype resulting from loss of motor neurons with TDP-43 pathology in ALS model mice ”
at The 49th Annual Meeting Society for Neuroscience San Diego, 2018.11.4. (Akamatsu, M)
November, 2018
Presentation on the title of ”ADAR2-mediated RNA editing of extracellular liner and circular RNAs: a potential biomarker of amyotrophic lateral sclerosis ”
at the The 49th Annual Meeting Society for Neuroscience San Diego, 2018.11.3.(Hosaka, T)
November, 2018
Presentation on the title of ”A aptamer as a potential drug candidate for ALS ? rescue of clinicopathologic ALS phenotype in model mice ”
at the Neurobiology of Disease, San Diego, 1-2 November 2018.(Akamatsu, M)
November, 2018
Presentation on the title of ”ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs ” Neurobiology of Disease,
at the Neurobiology of Disease, San Diego, 1-2 November 2018.(Hosaka, T)
June, 2018
Presentation on the title of ”Development of ALS therapy using AMPA receptor RNA aptamers ”
at the 4th EAN Congress, Lisbon 16-19 (16) . 2018.6. (Kwak, S)
September, 2017
Presentation on the title of ”SEARCH FOR ALS-ASSOCIATED EXTRACELLULAR RNA AS A BIOMARKER ”
at the WCN2017: XXIII World Congress of Neurology, Kyoto International Conference Center, Japan, September 17, 2017. (Hosaka, T)
Presentation on the title of ”ROBUST BENEFICIAL EFFECTS OF A NON-COMPETITIVE AMPA RECEPTOR ANTAGONIST IN AN ALS MOUSE MODEL ”
at The 27th International Symposium on ALS/MND, Convention Centre Dublin, Ireland, December 8, 2016. (Akamatsu, M)
November, 2016
Presentation on the title of ”A selective non-competitive AMPA receptor antagonist as a potential drug for sporadic amyotrophic lateral sclerosis (ALS) -rescue of motor dysfunctions and loss of motor neurons with TDP-43 pathology in ALS model mice ”
at the Society for Neuroscience 2016, San Diego Convention Center, USA, November 13, 2016. (Akamatsu, M)
November, 2016
Presentation on the title of ”Death of motor neurons caused by failure of GluA2 RNA editing was robustly rescued by a selective AMPA receptor antagonist in the mechanistic ALS model mice: a potential drug for sporadic amyotrophic lateral scleroses(ALS) ”
at the 10th , Paradise Point, USA, November 10, 2016. (Akamatsu, M)
Special Lecture on the title of ”Development of specific therapy for sporadic ALS“
at 【3rd World Centenarians Initiative】International Symposium on Amyotrophic Lateral Sclerosis, at Senri Life Science Center , JAPAN, February 19, 2016. (Kwak, S)
December, 2014
Presentation on the title of ”ADAR2 down-regulation, a pathogenesis of ALS and a target for therapy
"The Batsheva de Rothschild Seminar on RNA Editing-From Prediction to Function" in RNA editing workshop, at Ein Gedi Resort Hotel, Israel, December 7-10, 2014. (Kwak, S)
September, 2014
Updated the link.
August, 2014
Special Lecture on the title of ”Mechanism-based gene therapy for ALS“
at the 5th ALS Forum, at Sheraton Miyako Hotel Tokyo, Tokyo, August 23, 2014. (Kwak, S)
June, 2014
Presentation on the tiile of ”Calpain Plays a Crucial Role in TDP-43 Pathology “ in the symposium of ”Progress of TDP-43 research“ at 55th Annual Meeting of the Japanese Society of Neurology, Fukuoka, May 21,
2014.(Yamashita, T)
March, 2014
Special lecture on the title of ”A Step for Mechanism-Based ALS Therapy“
at the International Symposium of ”New Frontier of Molecular Neuropathology
2014“, Tokyo, March 16-17, 2014. (Kwak, S)
Japanese